HIV
Conditions
Interventions
Observation group:NA
Sponsors
Chest Hospital of Guangxi Zhuang Autonomous Region
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=18 years old; 2. Have been diagnosed as HIV-1 positive, have been on ART for more than 12 months, and have at least one HIV RNA at the lower limit of detection in the last six months; 3. Patients with dyslipidemia or borderline elevated blood lipids in at least one of the four measures, abnormal weight increase within 1-2 years after the start of ART, or body mass index (BMI) >=24 kg/m2, were judged by the investigators to be suitable for conversion to ANV-containing therapy; 4. Able to understand and comply with the requirements of the study protocol and voluntarily sign a written informed consent;
Exclusion criteria
Exclusion criteria: 1. Previous drug resistance results showed the presence of non-nucleoside drugs, lamivudine, tenofovir resistance mutations; 2. In the course of previous treatment, there was a change of treatment schedule due to failure of non-nucleoside drugs; 3. Any severe metabolic disease judged by the investigator to be unsuitable for the study; 4. Have major mental illness such as schizophrenia, epilepsy, major depression/anxiety; 5. Is currently suffering from AIDS related diseases and accept through CYP2C19 metabolism of drugs; 6. Have a history of drug use, recent history of alcohol or drug dependence; 7. Any condition that the investigator believes may compromise the safety of the subject and affect adherence to the protocol; 8. Participants who participated in clinical trials of other drugs or therapeutic devices within 30 days prior to enrollment in the study; 9. Systemic immunosuppressive therapy or immunomodulators were used within 30 days prior to treatment in this study, or users could not be avoided during the clinical trial; 10. Alanine aminotransferase or aspartase > 5×ULN; 11. Creatinine >=1.5×ULN or glomerular filtration rate (GFR) <=60ml/min/1.73 m^2 according to CKD-EPI creatinine formula; 12. Have a history of allergy or hypersensitivity to any ingredient or excipient of the investigational drug; Women who are pregnant or breastfeeding, and women of childbearing age who have a need to have a child within two years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HIV RNA viral load detection;CD4 T cell count test; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urea nitrogen; | — |
Countries
China
Contacts
Public ContactHuang Wei
Chest Hospital of Guangxi Zhuang Autonomous Region
Outcome results
None listed